| Project/Area Number |
25871161
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Laboratory medicine
Pathological medical chemistry
|
|---|
| Research Institution | Juntendo University (2015)
National Cancer Center Japan (2013-2014) |
|---|
Principal Investigator |
KUBOTA DAISUKE 順天堂大学, 医学部, 非常勤助教 (70638197)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 骨肉腫 / 化学療法抵抗性 / バイオマーカー / マイクロRNA / 化学療法奏効性 / 悪性骨腫瘍 / 個別化医療 |
|---|
| Outline of Final Research Achievements |
Osteosarcoma is the most common malignant bone tumor. Patients who respond poorly to chemotherapy are at higher risk of adverse prognosis. In this study, we aimed to identify novel chemo-responsiveness biomarkers. We investigated miRNA expression in eight open biopsy samples using miRNA-microarray analysis. We found six miRNAs were differentially expressed in patients who respond poorly to treatment. In functional study, overexpression of miRNAs in three osteosarcoma cell lines enhanced cell proliferation, invasiveness, and resistance to chemotherapeutic drugs. In addition, overexpression of miRNAs blocked the ability of these chemotherapy agents to induce apoptosis. Finally, the association between poor prognosis and the abundance of miRNAs was confirmed by qRT-PCR in 20 additional osteosarcoma patients. In conclusion, these miRNA biomarkers may be used as basis for risk stratification therapy in osteosarcoma.
|
